Eurohealth (USA), Inc. — a U.S. holding/operating entity inside the Hikma Pharmaceuticals PLC group. Hikma Pharmaceuticals PLC (LSE: HIK; NASDAQ Dubai: HIK; OTC: HKMPY) is a UK-headquartered, London-listed multinational founded in 1978, with roughly 9,100–9,600 employees and 2024 core revenue of about $3.16 billion (market cap ~$4.2 billion). Court filings identify Hikma Pharmaceuticals PLC as Eurohealth (USA), Inc.'s corporate parent, listing it alongside Hikma Labs Inc., Hikma Pharmaceuticals USA Inc., Roxane Laboratories, Inc. and West-Ward Pharmaceuticals Corp. A City of Columbus legislative record describes West-Ward Columbus Inc. and Hikma Pharmaceuticals USA Inc. as sister subsidiaries "under the Eurohealth Inc. parent organization." Eurohealth (USA), Inc. also appears as an original guarantor under Hikma's 2015 note deed of guarantee. It is not separately traded and does not publish standalone financials.
Operations: Eurohealth (USA), Inc. is a Hikma group company rather than an independent product marketer. Hikma's business — and the U.S. generics operations with which Eurohealth is grouped — spans three segments: generic and specialty injectables for hospitals (~42% of sales), generics (oral solids/liquids, nasal sprays and respiratory products, sold to the U.S. retail market from Hikma's Columbus, Ohio plant, ~33%), and branded generics and in-licensed products in MENA (~24%). The U.S. is Hikma's largest market (~61% of sales).
Litigation posture: Eurohealth is purely a defendant in the tracked data (0 plaintiff cases, 2 defendant cases) — consistent with an operating company being sued, not an NPE. Both tracked matters are antitrust, not patent-infringement, suits arising from Xyrem (sodium oxybate) generic-delay allegations rather than from Eurohealth asserting patents. Venues were the Eastern District of New York and the Middle District of Florida; both were centralized into In re Xyrem (Sodium Oxybate) Antitrust Litigation, MDL No. 2966 (N.D. Cal.).
Notable cases: UFCW Local 1500 Welfare Fund v. Jazz Pharmaceuticals Ireland Ltd. et al. (E.D.N.Y., filed 2020-06-30) and Blue Cross & Blue Shield of Florida, Inc. v. Jazz Pharmaceuticals, Inc. et al. (M.D. Fla., filed 2023-12-11) are third-party-payer class actions alleging Jazz and generic manufacturers, including the Hikma/Eurohealth entities, used patent settlements to delay generic Xyrem competition. Eurohealth's exposure is derivative of its Hikma affiliation; I could not verify a separate corporate website or independent headcount for the entity.